Close this search box.

Rapid Results: The RapidGen™ CRISPR Approach

RapidGen™ - Your fast lane to 2024 target validation breakthrough

Knock-Out your drug development efforts in 2024

Our RapidGen™ technology executes proof-of-concept or viability testing of your pre-clinical drug model in about a month. Our industry experts utilize a revolutionary CRISPR approach to break a gene or functional domain at multiple sites, followed by rapid phenotypic assays to immediately recover viable target hits. This method, which involves targeted double-strand breaks, enables the formation of loss-of-function mutations and the generation of knock-out lines (KO lines) that are essential for understanding the function mutation impacts and behavioral phenotypes in disease models.

Save your time and resources with our new RapidGen™ model

Our novel approach to utilizing zebrafish as a disease model for drug development provides our valued customers with early decision-making regarding their new functional genetic model. The use of transgenic lines and mutagenesis rate analysis in zebrafish allows for the precise identification of mutant alleles and function phenotypes, making it a choice for target site validation in the research community. Our technology facilitates the generation of zebrafish lines with specific KO-induced phenotypes, including teratogenic phenotypes, which are crucial for the assessment of drug safety and efficacy. Error-prone mechanisms associated with CRISPR editing are meticulously managed to ensure high-quality method descriptions and options for target site validation. The alleles in zebrafish serve as an ideal system for observing the formation of stable mutant lines and the double-strand break repair processes, enhancing our understanding of gene function and its implications for drug discovery. Furthermore, our effective F0 knockout method ensures the rapid generation of mutant fish with desired target effects at the one-cell stage embryos, enhancing the precision of our approach in identifying complex phenotypes. Our RapidGen™ technology also incorporates efficient methods to analyze target sites for CRISPR efficiency, utilizing confocal images to capture the intricate details of protein structure and mutant phenotypes. This is particularly useful in studying cell-autonomous functions and target activity, which are vital in understanding biological processes under various experimental conditions. See our infographic here summarizing the key competitive advantage our RapidGen™ service offers as you are mapping out your pre-clinical drug development timeline goals. RapidGen™ Technology Infographic

Contact Our Experts Today

We are dedicated to assisting you in your pre-clinical drug development efforts.

About The Author

Adam Saunders

After studying music at Indiana University, Adam pivoted into biology where he was introduced to C. elegans while working with Dr. Susan Strome and Dr. Bill Saxton. From there, Adam earned a Ph.D. from the Stanford University School of Medicine with Dr. Phil Beachy. In his thesis work, Adam investigated how signaling proteins essential for animal development are packaged and transported through the body. As a postdoctoral researcher with Dr. Victoria DeRose at the University of Oregon, Adam studied how beneficial and disease-causing bacteria use structured RNAs to detect nutrients with a human host. While at Oregon, Adam also taught advanced biology courses and served as a STEM outreach coordinator. Adam joined NemaMetrix (now InVivo Biosystems) as a Research and Development Scientist in April 2019. One of his roles is to oversee experimental design and execution of custom research projects. Adam still plays music–joining groups or jam sessions in the Eugene area–and also enjoys exploring the Oregon mountains by ski or by foot.

Share this articles

Picture of Adam Saunders

About the Author:

Connect with us